Provention Bio brought back down to earth as FDA panel narrowly backs diabetes prevention drug

Provention was flying high on Tuesday when an FDA advisory panel seemed to back the efficacy of its diabetes prevention drug, even after the agency flagged some issues with the data package supporting the therapy’s application a month earlier. But the company is not out of the woods yet, with the final vote only narrowly…